Squamous Cell Carcinoma | Norton Healthcare

Indication: Squamous Cell Carcinoma

A Phase 2 Study of the Combination of Pepinemab and Pembrolizumab in Patients with Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Sub-indication: Head and Neck Cancer

Study Type: Drug Study

Principal Investigator: Jaspreet Grewal, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Vaccinex Inc.

Learn more at ClinicalTrials.gov

Email for more information: Head&Neck-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.